| REVIEW ARTICLE |
|
| Year : 2012 | Volume
: 39
| Issue : 1 | Page : 7-9 |
|
|
Inducible clindamycin resistance in Staphylococci: Should clinicians and microbiologists be concerned?
Madhumati Kamat, MA Vagarali, SG Karadesai
Department of Microbiology, J.N. Medical College, Belgaum, Karnataka, India
Correspondence Address:
Madhumati Kamat
Department of Microbiology, J.N. Medical College, Belgaum, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-5009.96459
|
|
|
The increasing incidence of a variety of infections due to Staphylococcus aureus and the expanding role of community-associated methicillin-resistant S. aureus has led to an emphasis on the need for safe and effective agents to treat both systemic and localized Staphylococcal infections. Several newer antimicrobial agents are available for treatment of systemic Staphylococcal infections, but their use may be limited by the relatively high cost of these agents or the need forparenteral administration. Clindamycin has been used successfully to treat soft-tissue and musculoskeletal infections due to MRSA, in adults and children. However, concern over the possibility of the emergence of clindamycin resistance during therapy has discouraged some clinicians from prescribing that agent. Simple laboratory testing (e.g., the erythromycin-clindamycin 'D-zone' test) can separate strains that have the genetic potential (i.e., the presence of erm genes) to become resistant during therapy, from strains that are fully susceptible to clindamycin. |
|
|
|
| [FULL TEXT] [PDF Not available]* |
|
 |
|
